Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy - Transplantation and Cellular Therapy astctjournal.org/article/S26…
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day 30 post CAR T-cell therapy in non-Hodgkin lymphoma | Haematologica haematologica.org/article/vi…
Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis | Bone Marrow Transplantation nature.com/articles/s41409-0…
Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation | Bone Marrow Transplantation nature.com/articles/s41409-0…
Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy—a guidance by the GoCART Coalition Pharmacist Working Group | Bone Marrow Transplantation nature.com/articles/s41409-0…
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study | Bone Marrow Transplantation nature.com/articles/s41409-0…
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the EBMT nature.com/articles/s41409-0…